je.st
news
Tag: head
Historic Gay Head Lighthouse completes 135-foot move
2015-05-31 07:11:52| Energy - Topix.net
The 160-year-old lighthouse started its... . Tyler Finkle, project manager from International Chimney in Buffalo, N.Y., examines the original footing, believed to be from the 1840s, after the Gay Head Lighthouse was moved about 50 feet in Aquinnah, Mass., on the island o... A handful of volunteers trudged along the muddy and brush-filled banks of the Blanco River in Central Texas, searching for a group of people still missing days after the vacation house where they were staying was... The seemingly ceaseless rain has ended in North Texas and Oklahoma, but residents in the greater Houston area warily eyed the swollen Brazos River and the skies, which threatened to drop up to 5 additional inches of rain... The newly legal hemp industry is entering its second growing season with some big questions for producers experimenting with marijuana's non-intoxicating cousin.
Historic Gay Head Lighthouse completes 135-foot move
2015-05-31 00:20:07| Oil & Gas - Topix.net
The 160-year-old lighthouse started its... . Tyler Finkle, project manager from International Chimney in Buffalo, N.Y., examines the original footing, believed to be from the 1840s, after the Gay Head Lighthouse was moved about 50 feet in Aquinnah, Mass., on the island o... A handful of volunteers trudged along the muddy and brush-filled banks of the Blanco River in Central Texas, searching for a group of people still missing days after the vacation house where they were staying was... The seemingly ceaseless rain has ended in North Texas and Oklahoma, but residents in the greater Houston area warily eyed the swollen Brazos River and the skies, which threatened to drop up to 5 additional inches of rain... The newly legal hemp industry is entering its second growing season with some big questions for producers experimenting with marijuana's non-intoxicating cousin.
New Findings Show Durable Anti-Tumor Activity with KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status
2015-05-29 20:06:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Results from KEYNOTE-012, the First and Largest Study to Date of an Anti-PD-1 Therapy in Head and Neck Cancer, to be Presented at 2015 ASCO Annual Meeting KEYTRUDA Monotherapy Achieved Overall Response Rate of 25 Percent in Heavily Pre-treated Patients Merck is Advancing a Broad Head and Neck Clinical Program for KEYTRUDA with Five Clinical Trials, Across Multiple Lines of Therapy and in Combination with Other Agents KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new investigational data evaluating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy from the KEYNOTE-012 Phase 1b study in 132 pre-treated patients with recurrent or metastatic head and neck cancer, regardless of PD-L1 expression status. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: show
advanced
status
head
American Airlines names executive to head regional carrier Piedmont Airlines
2015-05-29 18:58:23| Airlines - Topix.net
American Airlines said Friday that it is appointing US Airways executive Lyle Hogg as president of its Piedmont Airlines subsidiary. Hogg has been vice president of flight operations for US Airways.
Tags: american
head
names
regional
Amgen and Merck Announce Expansion of Collaboration to Support Studies of Talimogene Laherparepvec in Combination with KEYTRUDA (pembrolizumab) in Patients with Head and Neck Cancer
2015-05-29 14:30:32| Merck.com - Product News
Dateline City: THOUSAND OAKS, Calif. and KENILWORTH, N.J. Companies Also Plan to Initiate Phase 3 Trial in Combination for Advanced Melanoma THOUSAND OAKS, Calif. and KENILWORTH, N.J., - May 29, 2015 Amgen (NASDAQ: AMGN) and Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgens investigational oncolytic immunotherapy, in combination with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Language: English read more
Tags: with
support
head
studies
Sites : [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] next »